heptavalent botulinum vaccine

**Heptavalent botulinum vaccine** refers to an investigational multivalent vaccine concept designed to induce protective neutralizing antibodies against all seven classical botulinum neurotoxin serotypes A through G. In the literature and patent record, such vaccines have generally been described as recombinant protein or DNA-based immunogens built from non-toxic fragments of botulinum neurotoxin, especially heavy-chain receptor-binding domains, with the goal of preventing botulism caused by *Clostridium botulinum* neurotoxins. Unlike the licensed heptavalent botulism antitoxin BAT, this is a prophylactic vaccine concept rather than a post-exposure antitoxin product. Publicly available sources support the existence of botulinum neurotoxin vaccine platforms and mono- or multivalent vaccine approaches, but do not clearly identify a single marketed product, unique brand name, or consistently named clinical-stage asset specifically called heptavalent botulinum vaccine.

Other names

heptavalent botulinum vaccinebotulinum neurotoxin vaccinemultivalent botulinum vaccine